This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Achieve Life Sciences (ACHV) Receives a Buy from Canaccord Genuity

Tipranks - Tipranks - Wed Jun 24, 6:44AM CDT

In a report released today, Gary Nachman from Canaccord Genuity reiterated a Buy rating on Achieve Life Sciences, with a price target of $13.00.

TipRanks' Prime Week Sale - 70% Off

Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Achieve Life Sciences, and ADMA Biologics. According to TipRanks, Nachman has an average return of 0.3% and a 46.08% success rate on recommended stocks.

Currently, the analyst consensus on Achieve Life Sciences is a Strong Buy with an average price target of $13.20.

See today’s best-performing stocks on TipRanks >>

Based on Achieve Life Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.17 million. In comparison, last year the company had a GAAP net loss of $12.83 million

Read More on ACHV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).